potential anti-inflammatory agents some of the compounds not only showed anti-inflammatory activity comparable to Phenylbutazone but were also found to be much less ulcerogenic. The research in this area led to development of Clidanac, 2) having ED 30 of 0.85 mg/kg, which showed better gastrointestinal tolerability. An isomer of Clidanac, 6-chloro-5-(cyclopentylmethyl)indan-1-carboxylic acid was also devoid of any mucosal damage in the rat stomach upto highest tested dose of 400 mg/kg. 6) It has been shown that the biochemical differences between the cyclooxygenase (COX) isoforms can be exploited to improve upon the selectivity of carboxyl containing nonsteroidal anti-inflammatory drugs (NSAIDs) as COX-2 inhibitors. Successful transformation of indomethacin and meclofenamic acid into selective COX-2 inhibitors by a single chemical derivatisation (amidation or esterification) has been reported. 7) Structurally diverse indomethacin amides inhibited purified human COX-2 with IC 50 values in the low nanomolar range but did not inhibit ovine COX-1 activity at concentrations as high as 66 mM. 8) Keeping the above points in view, we designed ( Fig. 1) , synthesized and biologically evaluated some amide derivatives of 6-chloroindan-1-acetic acid for anti-inflammatory and related biological activities. The idea behind derivatisation was to further lower the side effects of gastric irritation and ulceration, which is associated with free carboxyl group. Neutralization of the carboxyl group by amidation was expected to increase the activity profile of indan-1-alkanoic acids by not only enhancing absorption due to increased lipophilicity but also by imparting COX-2 selectivity.
Chemistry The starting reagent for the preparation of the key intermediate, (6-chloro-2,3-dihydro-1H-inden-1-yl)-acetic acid (5) was 3-chlorobenzaldehyde (1). Compound 1 was reacted with two moles of ethylacetoacetate (EAA) in presence of catalytic amount of piperidine at room temperature to obtain the substituted phenylbisacetoacetate (2) . Acid hydrolysis (end product is acid) of 2 was carried out with 6N potassium hydroxide (KOH) in 50% ethanol to get the diacid 3. The IR spectra of 3 showed broad OH stretch at 3400-2200 cm Ϫ1 and CϭO stretch at 1710 cm
Ϫ1
. 1 H-NMR of 3 showed doublet of doublet at d 2.58 and 2.70 ppm as well as quintet at 3.60 ppm for CH 2 and CH of glutaric acid side chain respectively, multiplet at d 7.18 ppm for aromatic protons and small broad singlet at d 10.79 ppm indicating the presence of carboxyl group.
Compound 3 was treated with aluminium chloride in the presence of catalytic amounts of sodium chloride when intramolecular Friedel-Craft's cyclization and hence ring closure took place to give the ketonic product 4. The cyclization was also tried with polyphosphoric acid but it gave poorer yields of keto product with more impurities. Presence of doublet of doublet at 2.46 and 2.58 ppm and doublet of doublet at 2.84 and 2.99 corresponding to CH 2 of side chain and CH 2 of the indan ring respectively as well as the presence of quintet at 3.79 ppm indicates the ring closure. The presence of aromatic protons (doublets at 7.38 and 7.65 ppm and singlet at 7.59) and acid protons (broad singlet at 10.91 ppm) further supports the proposed structure of compound 4.
The ketone group of compound 4 was finally removed using Clemmensen's reduction to give (6-chloro-2,3-dihydro-1H-inden-1-yl)acetic acid 5. Because of the different conformational arrangement of proton present on CH of indan ring both neighbouring CH 2 peaks got split into two peaks (two doublets of doublet at 2.48, 2.81 ppm and two multiplets at 1.78, 2.42 ppm). The presence of multiplet at 2.88 ppm equivalent to two protons in addition to peaks obtained for compound 5 indicates the reduction of carbonyl group and formation of indan ring system. The presence of aromatic protons (multiplet at 7.11-7.16 ppm) and proton of COOH group (small broad singlet at 11.18 ppm) further supports the structure of compound 5. Compound 5 was treated with oxalyl chloride in presence of catalytic amount of dimethylformamide to convert carboxyl group of 5 into acyl halide. The acyl halide thus obtained was not isolated or characterized. It was used directly in the next step. The acyl halide was reacted with various primary and secondary amines under Schotten-Baumann conditions for the formation of desired amides 6a-y. The structure of amide derivatives were confirmed by the presence of two, one or no peak around 3300 cm Ϫ1 (NH stretch) corresponding to primary, secondary and tertiary amides. Also disappearance of broad OH stretch at 3400-2400 cm Ϫ1 indicates the formation of amide bond. The formations of amides were further confirmed by presence of a small singlet at 5-8 ppm in 1 H-NMR. In most of the cases there was an overlap of two peaks at around 2.3-2.5 ppm corresponding to doublet of doublet and multiplet. Even for most of the aromatic amides, the NH peak was mixed with the aromatic peaks at around 7.1-7.3 ppm.
Results and Discussion
Anti-inflammatory Activity The anti-inflammatory activity of the test compounds was evaluated by carrageenaninduced rat paw edema model. The results (Table 1) show that the test compounds exhibit variable anti-inflammatory activity, and a few among them have significant acute as well as residual anti-inflammatory activity at 24 h after a single oral dose of 100 mg/kg p.o. Most of these amide derivatives were found to have more activity than the parent acid. The compounds were slow acting and showed longer duration of action. The peak activity of the test compounds was found to be lower than that of indomethacin (10 mg/kg, p.o.) but their residual activity at 24 h exceeded that of the latter. The lipophilicity of acid 5 is increased by amidation which leads to better absorption of these amide derivatives. Due to high lipophilicity of the amide derivatives in comparison to parent acid 5 (Table 1) these compounds are also likely to form lipid depots which might be the cause for their longer activity profile. The compounds 6a, 6p, 6w showed nearly 50% inhibition as the residual activity. The lower members in the aliphatic amides (having low log P values) showed almost negligible activity; however compound 6a was found to have good anti-inflammatory activity. That may be due to close resemblance of this compound to centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, which also possesses potent anti-inflammatory and analgesic activity. It has been reported in literature that this muscle relaxant has been taken in phase I clinical trials.
9) The tertiary amides (6l, 6m) and the cyclic amides (6i, 6j) showed intermediate activity. Among the aromatic series no generalized pattern of activity was found. The m-chloroaniline derivative (6p) was found to be the most active. The p-nitroaniline (6w) and ptoluidine (6t) derivatives also showed good anti-inflammatory activity profile while p-acetamidoaniline (6v) derivative showed least activity. The 4-aminopyridine derivative (6y) was found to be toxic at 100 mg/kg p.o. where as its isomer 3-aminopyridine derivative (6x) didn't show any toxicity at the same dose level. However at lower dose levels the compound 6y did not show any toxicity and in fact showed best anti-inflammatory activity with ED 30 of 6.45 mg/kg p.o.
Analgesic Activity The analgesic activity of the synthesized compounds at dose of 100 mg/kg p.o. was determined by acetic acid induced writhing assay. The results (Table 2) reveal that the beneficial effect of increasing chain length was apparent for analgesic activity to some extent with few exceptions. The compounds 6e, 6m, 6s and 6x exhibiting poor anti-inflammatory activities showed good analgesic activities while compound 6t exhibiting good anti-inflammatory activity showed poor analgesic activity. Among the cyclic analogs the cyclopentyl derivative (6i) was equipotent to its linear counterpart, 6g whereas the cyclohexyl derivative (6j) was less active than its linear counterpart (6h). The cyclic piperidino derivative (6l) showed intermediate activity while the piperazino derivative (6m) exhibited good analgesic properties. Among aromatic amides there was slight decrease in activity upon halogen substitution (6p, 6q, 6r) in comparison to aniline derivative (6o). Though m-toluidine derivative (6s) showed poor anti-inflammatory activity than para derivative (6t) the results were opposite for analgesic activity. The 3-aminopyridinyl derivative (6x) and the amide derivative (6a) showed maximum inhibition of 94% and 66% respectively and were more potent than standard drugs. Antipyretic Activity Few selected compounds were subjected to lipopolysaccharide (LPS)-induced hyperthermia assay. It is generally accepted that the NSAIDs exhibit their anti-inflammatory effect primarily through inhibition of prostaglandin synthesis. However, relatively recent in vitro studies have indicated that NSAIDs also interfere with peripheral proinflammatory cytokine production. 10, 11) It is well known that LPS produces a biphasic response in the rat. It shows an initial hypothermia up to 3 h of its administration. It has been shown that this hypothermia is triggered by tumour necrosis factor-a (TNF-a). 12) For determining the antipyretic activity two protocols were adopted, one in which the initial hypothermic phase was excluded and other in which the hypothermic phase was also monitored in order to determine if inhibition of TNF-a is involved in mechanism of action of these compounds. The test compounds (Table 3 ) exhibited significant antipyretic property at the dose level of 100 mg/kg p.o., as indicated by the temperature index. The compound 6a showed antipyretic activity comparable to that of aspirin. The isopropyl (6e), halogen substituted amine (6p, 6r), and 3-aminopyridino (6x) amide derivatives showed appreciable antipyretic activity. The data reveals that the test compounds exhibited significant antipyretic property, but these compounds did not exhibit antagonism of the initial LPS-induced hypothermia as indicated by first temperature index in Table 4 thus indicating that the antagonism of TNFa is not possibly involved in the mechanism of action of these compounds.
13)
Anti-arthritic Activity Compounds were selected for adjuvant-induced arthritis assay based on the inhibition of carrageenan-induced edema, analgesic and antipyretic activity profile. Adjuvant-induced arthritis test in rats produced a biphasic response. The initial response started immediately after adjuvant administration and reached maximum on 3rd day and then it started subsiding. The 2nd phase started from the 9th day and continued till the end of the experiment (14th day). Secondary lesions (appearance of nodules, and erythema in tail, nose and ears) started developing from the 10th day. Results of this test summarized in Table 5 show that compound 6w has the best profile in this assay. Compound 6a and 6w were found to be active and the animals did gain more weight than those treated with indomethacin indicating a better toxicity profile compared to the reference drug. In this biomodel though compounds 6a and 6w significantly reduced the primary inflammation of the right hind paw but these were not able to reduce the secondary inflammation of left hind paw as well as the development of secondary lesions. Seeing the activity profile of other tested compounds it can be said that in general these compounds exhibited poor anti-arthritic activity at tested dose level of 100 mg/kg p.o. Evaluation of Ulcerogenic Potential Some selected compounds (based on anti-inflammatory and analgesic activity profile) were tested for their ulcerogenecity potential. The tested compounds developed much lesser number of ulcerogenic lesions as indicated by ulcer index in comparison to the control ( Table 6 ). The nitro derivative (6w) showed no ulcer at tested dose level of 100 mg/kg p.o. It may, however, be noted here that the administration of the test compounds at the dose level of 100 mg/kg p.o. even for 14 d did not cause any ulceration of the gastric mucosa as revealed in the post mortem studies of sacrificed animals at the end of the adjuvant-induced arthritis study.
Studies with SKF-525A We hypothesized that the high residual anti-inflammatory activity of compounds could be due to higher protein binding of its active metabolite(s). These metabolites may arise via their hydrolytic metabolism to deamidated product. We, therefore, studied the anti-inflammatory activity of compounds 6a and 6p in carrageenan induced rat paw edema model using SKF-525A, a standard hepatic microsomal enzyme inhibitor, 14) pretreated rats. Examination of Table 7 reveals that there is no significant difference between data generated from this test and those generated using standard protocol. This indicates that probably the test compound per se is the active species.
Acute Toxicity Study The rats employed in anti-inflammatory screening were observed during 24 h. No mortality was present with these compounds except compound 6y at the end of observation period. The compounds 6a and 6p were also studied for their toxicity profile at higher dose levels. No toxicity was observed with these compounds upto the highest tested dose of 1000 mg/kg.
Conclusions
From the anti-inflammatory activity results it was found that compounds 6a, 6p, and 6w exhibited good anti-inflammatory activity. The compound 6y showed best anti-inflam- 630 Vol. 56, No. 5 matory activity at 25 mg/kg but it was found to be toxic at 100 mg/kg. These compounds were found to be longer acting and showed residual activity exceeding that of standard indomethacin. These compounds showed moderate analgesic activity profile with some variations from the anti-inflammatory activity data. The compound 6x was found to be most active with 94% inhibition in acetic acid induced writhings. Significant anti-pyretic activity in LPS induced pyresis was obtained and compound 6a showed lowest temperature index equivalent to that of aspirin. However the antagonism of TNF-a is not possibly involved in the mechanism of action of these compounds. The adjuvant induced arthritis study reveals that these compounds though have long duration of action are not effective in preventing the formation of secondary lesions. The compounds showed mild gastrointestinal toxicity in comparison to standard indomethacin. Consideration of results from the battery of the screening tests employed, it can be said that the test compounds 6a, 6p and 6w have the potential to turn out as drug candidates and thus they warrant further detailed studies regarding their pharmacological profile.
Experimental
Melting points were determined in open capillaries in a Buchi 530 melting point apparatus and are uncorrected. Identity and purity of the compounds were ascertained by TLC, elemental microanalysis and spectral analysis. Infrared-red spectra were recorded with a Shimadzu IR Prestige-21 FT-IR Spectrometer in KBr using powder diffraction technique.
1 H-NMR spectra were recorded on a 400 MHz Brucker Avance II NMR Spectrometer. Mass Spectra of the compounds were recorded in a Jeol SX 102/DA-6000 spectrometer. Elemental microanalysis was done in a Perkin-Elmer 2400 CHN analyzer. Chart 1 was followed for the synthesis of 6-chloroindan-1-acetic acid amides.
Diethyl 2,4-Diacetyl-3-(3-chlorophenyl)pentanedionate (2) 3-Chlorobenzaldehyde (1) (28 g, 0.2 mol) was dissolved in ethylacetoacetate (56 g, 0.43 mol) in a dry conical flask and piperidine (2.5 ml) was added slowly at ambient temperature and then kept for 3 d or more (up to seven days, depending on room temperature) with the mouth stoppered. The solid product thus obtained was crushed and then washed with solvent ether to get the desired product in 70-75% yield. 15) Recrystallisation from dil. alcohol gave the analytical product, mp 120-121°C, IR (cm 3-(3-Chlorophenyl)pentanedioic Acid (3) Compound 2 (40 g, 0.1 mol) was dissolved in a hot solution of KOH (160 g in 120 ml of water) and 160 ml of 50% ethanol was added. The hot reaction mixture was refluxed on a water bath for 1 h. Alcohol was then removed by distillation, and after dilution with water it was cooled and washed with solvent ether. The aqueous layer on acidification with cold conc. HCl with cooling gave crude 4 which was filtered and recrystallized from hot water. 15 Chloro-3-oxo-2,3-dihydro-1H-inden-1-yl) (6-Chloro-2,3-dihydro-1H-inden-1-yl)acetic Acid (5) Compound 4 was subjected to Clemmensen's reduction. 17) 0.1 mol of compound 4 was treated with 50 g of zinc amalgam, 50 ml of conc. HCl and 75 ml of water. Around 200 ml of benzene was added as a co-solvent. The reaction mixture was refluxed on steam bath for about 16 h (until the reaction mixture became keto-negative). The organic layer was separated and the aqueous layer and zinc granules were further extracted with benzene. The pooled organic phase was then dried over anhydrous sodium sulfate and was finally distilled off to get the reduced acid. The reduced acid obtained was a liquid and was subjected to vacuum distillation to get the pure compound. Yield 80-85%; distilled at 148°C/0.3 mmHg; IR (cm 
General Method for the Synthesis of Amide Derivatives (6a-y)
A solution of compound 6 in dry dichloromethane and catalytic amount of dimethylformamide was treated with oxalyl chloride in 1 : 2.5 molar ratios under ice cold conditions. The solution was allowed to stand for 24 h at room temperature with occasional stirring. Excess oxalyl chloride was removed by co-distillation with dry benzene under reduced pressure. The acyl halide thus obtained was not characterized or isolated and was used directly in the next step. To a solution of the acyl halide in dry dichloromethane was added a mixture of triethylamine (1.1 mol) and the appropriate amine in dichloromethane with constant stirring under ice-cold conditions. The mixture was kept at ambient temperature for 12 h. The resulting reaction mixture was then extracted with 0.1 N HCl, water, saturated solution of NaHCO 3 , brine and water. The organic phase was dried with anhydrous sodium sulfate and then distilled to obtain the title compounds. -2-(6-chloro-2,3-dihydro-1H-inden-1-yl)acetamide (6f Biological Evaluation All synthesized compounds were evaluated for analgesic and anti-inflammatory activity and few selected compounds were screened for antipyretic, ulcerogenecity and anti-arthritic activity. The test compounds, 6a-y, and standard drugs (indomethacin and aspirin) were administered orally as suspensions in 0.5% carboxymethylcelluse sodium in distilled water. Each group consisted of six animals. The animals were maintained at temperature of 24Ϯ2°C, relative humidity of 45% and kept under a 12 h light and dark cycle. The animals were fasted overnight for analgesic and anti-inflammatory assays and 24 h for antipyretic and ulcerogenecity studies. During fasting they had free access to water. The data obtained in pharmacological experiments was subjected to statistical analysis using student's t-test, one way ANOVA, post hoc test, and the chosen level of significance was pϽ0.05. The protocol for the animal experiments was approved by the Institutional Animal Ethics Committee (IAEC) as registered under Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Govt. of India.
N-Butyl
Acute Anti-inflammatory Activity The anti-inflammatory activity of the test compounds (6a-y) was determined by carrageenan-induced rat hind paw edema assay as described by Winter et al. 19) Female Wistar rats weighing 170Ϯ20 g were administered the test compounds and standard indomethacin orally equivalent to 100 mg/kg and 10 mg/kg respectively. One hour after dosing, 0.1 ml of 1% carrageenan was administered into the subplantar region of the right hind paw. The paw volumes were measured using an Ugo Basile plethysmometer at 0, 1, 2, 3, 4, 6 and 24 h after carrageenan injection. The results (Table 1) are expressed as percentage inhibition of edema formation. The percent inhibition of edema in each drug treated group was calculated using the formula given below:
where V c and V t are average edema volumes in control and treated groups respectively.
Analgesic Activity The analgesic activities of the compounds (6a-y) were determined by acetic acid induced writhing test in mice as described by Collier et al. 20) with minor modifications. Female Swiss albino mice, 20Ϯ5 g, were administered the test drugs orally at 100 mg/kg. and the standard indomethacin and aspirin at 10 mg/kg and 100 mg/kg respectively. One hour after the oral dosing they were injected i.p. with 0.1 ml/10 g of 1% v/v acetic acid. Five minutes after the injection the writhing (full extension of hind limbs) were noted for next 15 min. Animals giving 20 or more wriths were selected for the study. The percent inhibition by individual drug as well as by the reference standard drugs were calculated using the following formula,
where W c represents the average writhing produced by the control group and W t represents the average writhing produced by the test groups.
Antipyretic Activity The antipyretic activity of the compounds was evaluated by lipopolysaccharide induced pyrexia. Two protocols were adopted, first in which initial hypothermic phase was excluded and only antipyretic activity was evaluated and the second in which the hypothermic phase was also evaluated in order to determine if these compounds also inhibit TNF-a. The method was that of Dogan et al. 13) with minor modifications. Adult female Wistar rats (170Ϯ20 g) were used. Phenol extracted LPS from Eschericia coli serotype 0111: B4 (Difco) was used. The experiment was started at 0900 h. LPS dissolved in apyrogenic saline was injected at dose of 100 mg/kg i.p. After 3 h test compounds and aspirin were given orally at dose level of 100 mg/kg. Indomethacin was given at a dose level of 10 mg/kg. The rectal temperature was determined using telethermometer probes immediately before and 4, 5, 6, 7 h after LPS administration. For evaluation of antipyretic activity, the temperature index was calculated following the method of Winter et al. 21) In the second protocol after half an hour of oral administration of the drugs LPS dissolved in apyrogenic saline was injected at dose of 100 mg/kg i.p. The rectal temperature was determined using telethermometer probes immediately before and 1, 2, 3, 4, 5, 6, 7 h after LPS administration. Two temperature indexes were calculated, first at the end of 3rd hour and second at the end of 7th hour of observations.
Chronic Anti-inflammatory Activity The method used was essentially that of Newbould. 22) Only three compounds were selected for this study. Female albino rats weighing 160Ϯ10 g were chosen for the study. The animals were given the test compounds at the dose level of 100 mg/kg p.o. once daily for 14 d starting from the day before the administration of 0.1 ml Freund's complete adjuvant (Genie, Bangalore, India) into the subplantar surface of right hind paw of each rat. Indomethacin was taken as the standard drug and was given for 14 d at the dose level of 10 mg/kg p.o. Both hind paw volumes up to the fixed mark at the level of lateral malleolus were measured before and daily after adjuvant administration. The formation of nodules and appearance of erythema in tail, nose and ears were observed and graded as mild, moderate and severe for comparison. Change in body weight of the animals during the test period was also recorded for comparison. The results are presented in Table 6 .
Ulcerogenecity Test Only few amides from the series 6a-y were selected for ulcerogenic studies. The method used to evaluate the ulcerogenic potential of the test compounds was that of Velázquez et al. 23) with minor modifications. Twenty four hour fasted Wistar female rats (175Ϯ25 g) were used. The test compounds and the standard drug indomethacin were dosed orally at 100 mg/kg and 30 mg/kg respectively. After six hours of oral dosing the rats were sacrificed using cervical dislocation. The stomachs were taken out and cut along the greater curvature. After washing with saline the stomach mucosa was examined for ulcers using a hand lens. The gastric lesions were counted, and an ulcerative index (UI) for each animal was calculated according to Szelenyl and Thiemer 24) ; UIϭ(n lesion I)ϩ(n lesion II)2ϩ(n lesion III)3
Where: Iϭpresence of edema, hyperemia and single, submucosal, punctiform hemorrages (petechiae) IIϭpresence of submucosal, hemorrhagic lesions with small erosions; IIIϭpresence of deep ulcer with erosions and invasive lesions Metabolism Inhibition Study Using SKF-525A
13)
The rats were pretreated with SKF 525A (50 mg/kg i.p.). One hour later, the rats were dosed orally the test drug 6a and 6p at 100 mg/kg. The remaining protocol followed was the same as that of anti-inflammatory screening by carrageenan induced rat paw edema model.
